The patients were randomized to treatment with a paclitaxel-eluting stent or vascular brachytherapy
using any Food and Drug Administration-approved, [beta]-source radiation system.
Sponsored by Best Vascular, the breakfast symposium will update the status of vascular brachytherapy
and the BetaCath(TM) of Novoste for 2006 and will feature presentations on the treatment of drug-eluting stent restenosis with vascular brachytherapy
and five-year clinical follow-up data with the BetaCath(TM) system.
Novoste Corporation (NASDAQ: NOVT) today announced the results of its Post Approval Studies (PAS), which included the three-, four-, and five-year follow-up of the STents And Radiation Therapy (START) and STents And Radiation Therapy 40 (START 40/20) trials, which further demonstrated that routine application of vascular brachytherapy
(VBT) is effective in the treatment of in-stent restenosis beyond the earlier reported two-year follow-up.
Best Vascular, an affiliate of Best, has been established for the purpose of focusing on the vascular brachytherapy
business to be acquired from Novoste.
Novoste Corporation, based in Atlanta, GA, develops advanced medical treatments for coronary and vascular diseases and is the worldwide leader in vascular brachytherapy
We have considerable experience in the radiation field and specific experience serving the vascular brachytherapy
We look forward to the exhibition of our I-Plant(TM) Iodine-125 radioactive seeds and our coronary vascular brachytherapy
devices at this prestigious meeting of radiation oncology physicians," stated Dr.
Consistent with its review of strategic alternatives, Novoste has received expressions of interest from several parties to acquire the assets of Novoste's existing vascular brachytherapy
Norcross, Georgia-based Novoste Corporation is a world leader in the emerging field of vascular brachytherapy
, the use of intravascular radiation to reduce the incidence of restenosis.
A 16-year veteran of the interventional and endovascular medical device industry, Snyder has held professional sales management positions with several high profile device makers and played a key role in the highly successful launches of Novoste's vascular brachytherapy
registry trial, which further demonstrated that routine application of intracoronary radiation therapy, also known as vascular brachytherapy
(VBT), is highly effective in the treatment of restenosis following coronary angioplasty and stent procedures.
Novoste Corporation (NASDAQ: NOVT) today announced that its Board of Directors has determined that its vascular brachytherapy
(VBT) business is no longer viable and, as a result, has authorized a staged, wind-down of the business.